FDA Approves JUVÉDERM VOLBELLA XC for Undereye Hollows
Allergan Aesthetics, an AbbVie company, announces the FDA approval of JUVÉDERM VOLBELLA XC for improvement of infraorbital hollows in adults over the age of 21.
Allergan Aesthetics, an AbbVie company, announces the FDA approval of JUVÉDERM VOLBELLA XC for improvement of infraorbital hollows in adults over the age of 21.
The injectable, known as Restylane Contour in the US, achieved a 94.4% responder rate at six months, with improvements sustained through 12 months.